Gamma Knife Radiosurgery for Petroclival Meningioma: Long-Term Outcome and Failure Pattern
Overview
Authors
Affiliations
Total removal of petroclival meningioma is difficult, and aggressive extirpation is often associated with significant surgical morbidity and mortality. The aim of this study was to evaluate the long-term outcome and failure pattern of treatment with Gamma Knife radiosurgery (GKRS) in patients with petroclival meningiomas. Eighty-nine consecutive patients with petroclival meningiomas underwent GKRS between 1998 and 2013. Fifty-eight patients received GKRS as a primary treatment and 31 patients underwent GKRS as a secondary treatment after microsurgery. The mean tumor volume was 6.7 cm3 (range, 0.5-46.3 cm3) and the mean marginal dose was 13.2 Gy (range, 8-17 Gy). At the last radiological follow-up, tumor volume was decreased in 50 patients (56.2%), stationary in 34 patients (38.2%), and increased in 5 patients (5.6%). The actuarial progression-free survival after GKRS was 94.7% at 5 years and 88.9% at 10 years. Favorable cranial nerve outcomes were found in 81 patients (91%). A regrowth pattern was present in all 4 patients of the primary treatment group, whereas cyst formation (3 patients) and regrowth (1 patient) were observed in the secondary treatment group. GKRS is an effective and reasonable option as a primary or secondary treatment for petroclival meningioma. Further studies of failure patterns after GKRS for petroclival meningioma are mandatory.
Gamma Knife radiosurgery for meningiomas of the confluence of the falx and tentorium.
Abdallah H, Mallela A, Wei Z, Abou-Al-Shaar H, Niranjan A, Lunsford L J Neurooncol. 2022; 161(2):225-233.
PMID: 36125641 DOI: 10.1007/s11060-022-04125-1.
Inoue T, Goto Y, Shima A, Hirai H, Shitara S, Suzuki F Acta Neurochir (Wien). 2022; 164(9):2465-2471.
PMID: 35869331 DOI: 10.1007/s00701-022-05291-x.
Midline Skull Base Meningiomas: Transcranial and Endonasal Perspectives.
Mastantuoni C, Cavallo L, Esposito F, DAvella E, de Divitiis O, Somma T Cancers (Basel). 2022; 14(12).
PMID: 35740543 PMC: 9220797. DOI: 10.3390/cancers14122878.
Wijaya J, Arjuna Y, July J J Neurooncol. 2022; 159(1):33-42.
PMID: 35717468 DOI: 10.1007/s11060-022-04041-4.
Bin Alamer O, Palmisciano P, Mallela A, Labib M, Gardner P, Couldwell W J Neurooncol. 2022; 157(2):207-219.
PMID: 35301638 DOI: 10.1007/s11060-021-03934-0.